Clinical Trials › NCT06433752
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Sponsored by TG Therapeutics, Inc.
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 500
Target enrollment
29
U.S. states
Jul 2024
Start date
Jul 2027
Expected completion
Interventions / Treatments
No Intervention
Conditions studied
Relapsing Multiple SclerosisMultiple Sclerosis
Where this trial is running (79 sites)
Florida7 sites
Altamonte Springs · Boca Raton · Clearwater · +4 more
Colorado6 sites
Aurora · Basalt · Colorado Springs · +3 more
Ohio6 sites
Centerville · Centerville · Cincinnati · +3 more
Texas6 sites
Austin · Austin · Austin · +3 more
New Jersey5 sites
Cherry Hill · Freehold · Livingston · +2 more
California4 sites
Fresno · Newport Beach · Orange · +1 more
Wisconsin4 sites
Greenfield · Milwaukee · Neenah · +1 more
Arizona3 sites
Gilbert · Phoenix · Scottsdale
Illinois3 sites
Chicago · Evanston · Urbana
Massachusetts3 sites
Boston · Burlington · Norfolk
Michigan3 sites
Ann Arbor · Farmington · Owosso
North Carolina3 sites
Charlotte · New Bern · Raleigh
Virginia3 sites
Charlottesville · Norfolk · Vienna
Alabama2 sites
Birmingham · Mobile
Connecticut2 sites
Farmington · Hartford
Georgia2 sites
Atlanta · Atlanta
Kentucky2 sites
Lexington · Louisville
Maryland2 sites
Baltimore · Glen Burnie
New York2 sites
Amherst · New York
Tennessee2 sites
Knoxville · Nashville
Delaware1 site
Wilmington
District of Columbia1 site
Washington D.C.
Idaho1 site
Coeur d'Alene
Nebraska1 site
Omaha
Nevada1 site
Las Vegas
Oregon1 site
Portland
Pennsylvania1 site
Bethlehem
Washington1 site
Kirkland
West Virginia1 site
Morgantown
MS centers in Florida
Compare treatment centers near a trial site by center type, providers and trials.
View Florida centers